OraSure Technologies, Inc. (NASDAQ:OSUR – Get Free Report) passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $3.74 and traded as high as $4.18. OraSure Technologies shares last traded at $4.13, with a volume of 1,158,221 shares trading hands.
Analyst Ratings Changes
Several brokerages have commented on OSUR. Wall Street Zen upgraded shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research note on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of OraSure Technologies in a research report on Tuesday, September 1st. Finally, Zacks Research upgraded OraSure Technologies to a “hold” rating in a research report on Friday, October 2nd. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $3.00.
Read Our Latest Analysis on OraSure Technologies
OraSure Technologies Trading Up 8.7%
The firm has a market cap of $284.85 million, a P/E ratio of -5.99 and a beta of 1.03. The stock has a 50 day simple moving average of $3.72 and a 200-day simple moving average of $3.74.
Institutional Investors Weigh In On OraSure Technologies
Several large investors have recently bought and sold shares of OSUR. Hsbc Holdings PLC raised its stake in OraSure Technologies by 4.6% during the first quarter. Hsbc Holdings PLC now owns 141,309 shares of the medical instruments supplier’s stock valued at $421,000 after purchasing an additional 6,218 shares in the last quarter. Legal & General Group Plc bought a new position in OraSure Technologies during the second quarter valued at $30,000. Diversify Advisory Services LLC purchased a new position in shares of OraSure Technologies in the 2nd quarter worth $47,000. Diversify Wealth Management LLC purchased a new position in shares of OraSure Technologies in the 1st quarter worth $36,000. Finally, Two Sigma Securities LLC purchased a new position in shares of OraSure Technologies in the 2nd quarter worth $55,000. Institutional investors own 93.50% of the company’s stock.
About OraSure Technologies
OraSure Technologies, Inc develops, manufactures and markets diagnostic products and specimen-collection technologies used by healthcare providers, laboratories, researchers and consumers. The company focuses on making testing more accessible through products that support decentralized, point-of-care and at-home testing, as well as laboratory-based molecular and diagnostic workflows.
Its portfolio has included the OraQuick line of rapid diagnostic tests, including oral-fluid tests for HIV and hepatitis C, along with other infectious-disease testing products.
Further Reading
- Five stocks we like better than OraSure Technologies
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
